Marksans Pharma Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Sandra Saldanha, was filed 06 Jun 2024.
Marksans Pharma Limited: what insiders have been doing
Marksans Pharma Limited is a Health Care company. Its directors and officers file their transactions with SEBI (PIT + SAST). In the past year (28 October 2025 to 28 October 2026), 4 filings came from 4 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of Marksans Pharma Limited has been absent for the past year. The median gap between trade and publication is zero days: most filings appear on the same day. The shorter that gap, the sooner other investors can see what insiders have done.
With 4 filings in twelve months, the company is in line with the median of 4 filings across the 1,893 companies we follow on the same exchange. Looking back to 2023, when coverage begins, insiders filed 5 purchases and 3 sales.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
Since the insiders bought
- +62.1%Entry ₹156.25 · Close at T+365 ₹253.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Marksans Pharma Limited Strong Buy (bullish), based on 3 analysts. Average price target: ₹324.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 63,273 shares0EquityGiftSEBI:905aa6366c34c9a038ba63dd20361642d97366e4
- 145,000 shares0EquityGiftSEBI:2e781c4a64b186f28260d922b5e4347485c715cb
- 20,000 shares0EquityGiftSEBI:a168f4035bd0bd855171aed7b9c41603d2c79995
- 228,273 shares0EquityGiftSEBI:5fa5a852166715758ea3133ed1bcc2dbf17167e1
- 63,276 shares@ ₹141.482128.9% of flowEquity SharesSEBI:dfed11931fd014b6fe3f87a85ccfcb28c46c388dCanonical exit: 3 Sept 2024 (T+90)
- 47,000 shares@ ₹146.007222.2% of flowEquity SharesSEBI:3a0b28735ed78ab505161496a5f7e7e83147d053Canonical exit: 1 Sept 2024 (T+90)
- 3,000 shares@ ₹114.901719.4% of flowEquity SharesSEBI:2e2ad155d75bcf305923ea669f20b6a56aae7c3c
- 2,000 shares@ ₹163.921518.4% of flowEquity SharesSEBI:2fd199b725b329c9c77b357c4ed02f432ee90b37
- 6,500 shares@ ₹117.055242.7% of flowEquity SharesSEBI:f3f5c625f259ef795f1df82964f7141dd79b25e9
- 3,000 shares@ ₹115.7519.5% of flowEquity SharesSEBI:446619a36ecdecb12d4ddac15e4d4728e148189eCanonical exit: 12 Nov 2023 (T+90)
- 145,000 shares@ ₹66.6932.1% of flowEquity SharesSEBI:03115b70548a4d8d7e43c232df60d3b9b4bbd022Canonical exit: 12 Jun 2023 (T+90)
- 75,000 shares@ ₹67.460316.8% of flowEquity SharesSEBI:60104fd025db59c7aa8a27ffc42a73be37440538Canonical exit: 28 May 2023 (T+90)
- 1,000,000 shares@ ₹74.00100.0% of flowEquity SharesSEBI:cca991f42231edd239ddfebdb5677a9dbbdc2720
13 of 13 declarations
About Marksans Pharma Limited
Marksans Pharma Limited is a pharmaceutical company that specializes in the manufacturing of generic drugs and health products. It is listed on the XBOM market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
